Welcome to our dedicated page for Haleon plc SEC filings (Ticker: HLNCF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Haleon plc’s SEC filings document foreign-issuer reports covering capital structure, treasury-share activity, and financing disclosures. Recent Form 6-K reports include transactions in own shares under a buyback programme, ordinary-share and voting-rights totals, and notices used for ownership-notification calculations under FCA disclosure rules.
The filings also cover listing particulars for the Euro Medium Term Note programme of Haleon UK Capital plc and Haleon Netherlands Capital B.V., guaranteed by Haleon. Company descriptions in the reports identify Haleon as a consumer health company with product categories across oral health, vitamins and supplements, pain relief, respiratory health, digestive health, and therapeutic skin health.
Haleon plc reported purchases of 7,740,513 ordinary shares of £0.01 each for cancellation under its share buyback programme announced on 12 March 2026. The shares were bought on multiple UK trading venues between 7 and 10 April 2026 at prices around the mid‑370p range.
After settlement, Haleon’s registered share capital is 8,919,824,040 ordinary shares, of which 12,439,998 are held as treasury shares. This leaves 8,907,384,042 ordinary shares with voting rights, a figure shareholders can use when assessing disclosure thresholds under the FCA’s transparency rules.
Haleon plc reported that it purchased 5,266,782 ordinary shares of £0.01 each for cancellation under its share buyback programme announced on 12 March 2026. The shares were bought on 30 and 31 March and 1 and 2 April 2026 across multiple UK trading venues at prices generally between about 368p and 379p per share.
After settlement of these transactions, Haleon’s registered share capital is 8,927,564,553 ordinary shares, of which 12,493,360 are held as treasury shares. The number of ordinary shares with voting rights is now 8,915,071,193, a reference figure for FCA disclosure threshold calculations.
Haleon plc reports its share capital and voting rights position as at 31 March 2026. The company has issued 8,931,093,261 ordinary shares of £0.01 each, of which 12,548,735 are held in treasury. This leaves 8,918,544,526 ordinary shares carrying voting rights, which shareholders should use as the denominator when assessing whether they must notify holdings or changes in holdings under the FCA's Disclosure Guidance and Transparency Rules.
Haleon plc reports that it purchased 8,939,706 ordinary shares of £0.01 each for cancellation under its share buyback programme announced on 12 March 2026. The purchases took place between 23 and 27 March 2026 across the London Stock Exchange, CBOE (UK) and Aquis at prices between 353.7000p and 373.0000p per share.
After settlement, Haleon’s registered share capital is 8,932,831,335 ordinary shares, of which 12,548,735 are held as treasury shares. The number of ordinary shares with voting rights is now 8,920,282,600, which shareholders may use for disclosure thresholds under the FCA’s Disclosure Guidance and Transparency Rules.
Haleon plc reports that it has purchased 7,833,121 ordinary shares of £0.01 each for cancellation under its share buyback programme announced on 12 March 2026. The purchases were carried out on UK venues between 16 and 20 March 2026 at volume‑weighted average prices generally around the high‑370s to low‑390s pence per share.
After settlement of these transactions, Haleon’s registered share capital is 8,941,771,041 ordinary shares, of which 12,591,821 are held in treasury. This leaves 8,929,179,220 ordinary shares with voting rights, a figure shareholders can use for disclosure threshold calculations under the FCA’s transparency rules.
Haleon plc reported recent purchases of its own shares under a previously announced buyback programme. The company bought 2,749,486 ordinary shares of £0.01 each for cancellation on 12 and 13 March 2026 across the London Stock Exchange, CBOE UK venues and Aquis.
After these transactions settle, Haleon’s registered share capital will be 8,949,604,162 ordinary shares, including 43,651,673 held in treasury. This leaves 8,905,952,489 ordinary shares with voting rights, a figure shareholders can use for regulatory disclosure thresholds.
Haleon plc has published its 2025 Annual Report and Accounts & Form 20-F, together with the Notice of its 2026 Annual General Meeting. These documents are available on the company’s website and the Form 20-F is being filed with the SEC.
The 2026 AGM will be held as a virtual meeting at 3:00pm (BST) on 29 April 2026, with joining details set out in the AGM Notice. Shareholders can also request a free hard copy of the Annual Report, including the audited financial statements.
Haleon plc reported new share-based awards granted to its Chief Executive Officer and Chief Financial Officer under its long-term incentive and bonus deferral plans. On 12 March 2026, CEO Brian McNamara received conditional awards over 1,639,855 ordinary shares under the Performance Share Plan and 173,825 shares under the Deferred Annual Bonus Plan, both at nil cost. On the same date, CFO Dawn Allen received conditional awards over 712,784 shares under the Performance Share Plan and 95,513 shares under the Deferred Annual Bonus Plan, also at nil cost. The main Performance Share Plan awards are subject to performance conditions through 31 December 2028, are aligned with Haleon’s Directors’ Remuneration Policy, and are subject to malus and clawback provisions.
Haleon plc reported modestly lower 2025 revenue of £11,030m, slightly down from £11,233m in 2024, but delivered stronger profitability. Operating profit rose to £2,412m and profit after tax increased to £1,680m, lifting basic earnings per share to 18.6p from 15.8p.
Cash generation was solid, with net cash inflow from operating activities of £2,634m. The balance sheet strengthened as total liabilities fell to £16,146m and net assets grew to £16,484m. For 2025, dividends paid totalled £612m, and the Board proposes a further 4.9p final dividend.
The company highlights a focus on health and safety, with a 2025 reportable injury and illness rate of 0.14 per 100,000 hours and no fatalities. Cyber security remained a principal risk area, with a dedicated function, a CEO-led culture campaign, and no significant cyber incidents identified in 2025.
Haleon plc is starting a share buyback programme to repurchase its ordinary shares for up to an aggregate consideration of £500 million. The programme follows its 2025 preliminary full year results announcement and is aligned with its capital allocation priorities, including delivering attractive shareholder returns.
Haleon has signed an irrevocable agreement with HSBC Bank plc, which will independently decide the timing of purchases on the London Stock Exchange, CBoE Equities Europe, and Aquis, including during closed periods. The buyback begins immediately and will end no later than 19 August 2026.
Purchases before the 2026 Annual General Meeting will use the existing 2025 shareholder authority, and any later purchases will rely on authority sought at the 2026 AGM, if approved. All repurchased shares will be cancelled to reduce Haleon’s share capital, and there is no guarantee the full programme will be completed.